Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
1 evidence topic · 6 sources
Summary
Amivantamab with platinum-based chemotherapy is recommended for first-line treatment, and sunvozertinib has accelerated approval after platinum-based chemotherapy. Activity in one line of treatment does not establish comparative effectiveness in another. WU-KONG28 reported objective responses in 58.9% with sunvozertinib and 31.1% with chemotherapy. The evidence assembled here does not provide a randomized comparison of Zipalertinib against amivantamab-containing therapy or sunvozertinib.